WHO Database Proposal Seen Benefiting Indian Generics
This article was originally published in PharmAsia News
Indian drug makers expect to benefit from a portion of an international agreement drafted by the World Health Organization establishing a centralized database of drugs and the countries in which patents have been secured for them. Generics makers see the database as helping to dispel assumptions by some non-governmental organizations that a drug under patent in one country is protected in all nations. The head of the Indian Pharmaceutical Alliance noted that most multinational drug makers seek patents for their products in only 50 to 60 countries. (Click here for more
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.